British pharmaceutical giant AstraZeneca announced the “innovative” results of a new drug for breast cancer, which is said to reduce the risk of death or disease progression by 72 percent, compared to current treatments.
The drug company said the results of its Enhertu drug trial in the treatment of currently incurable breast cancer showed “a strong trend towards survival and improvement.”
AstraZeneca said that Enherthu, when combined with chemotherapy, was shown to be twice as effective in controlling the disease as antibody treatment which is the current standard of medicine against this disease.
Three-quarters of the 500 patients tested from around the world who were treated with Enherthu showed no disease progression after 12 months, compared with 34.1% of those treated with TDM1. Moreover, survival improved from 7.2 months to 25.1 months.
In total, 94.1% of patients treated with Enhertu survived 12 months of treatment, compared with 85.9% of patients with TDM1.
Susan Galbraith, executive vice president of Oncology Research and Development at AstraZeneca, called the results “innovative.”
“These unprecedented data represent a possible paradigm shift in the treatment of HER-2-positive metastatic cancer and illustrate the potential for Enhertu to transform more patient lives into previous treatment settings,” she said.
Enhertu was approved by the Food and Drug Administration in 2019 for inoperable or metastatic HER-2 breast cancer if the patient did not respond to standard treatment and at least two other combination options.
“With the extraordinary results of this study, Enhertu could become the new standard of care for patients with metastatic breast cancer HER-2 who are positive after standard chemotherapy,” said Dr. Sunil Verma, Vice President and Clinical Chief of Global Research of breast cancer in AstraZeneca.
According to the American non-profit organization Breastcancer.org, about one in eight women will experience invasive breast cancer in their lifetime, although the overall death rate has declined over the years, largely due to advances in treatment and early detection through screening. .
By 2021, about 250,000 new cases of invasive breast cancer are expected to be diagnosed in women in the US and about 40,000 women in the US are in serious condition.
Moreover, there are around 360,000 new cases of breast cancer diagnosed and 92,000 deaths each year in Europe. In Israel, about 4,500 women are diagnosed each year and 900 die.
To be part of the group »AOL“just click: Join Group and your request will be approved immediately.